Observations placeholder
Tetrabenazine
Identifier
024166
Type of Spiritual Experience
Number of hallucinations: 32
Background
A description of the experience
Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders. It is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand, some parts of Europe and in the United States as an orphan drug. On August 15, 2008, the U.S. Food and Drug Administration approved the use of tetrabenazine to treat chorea associated with Huntington's disease. Although other drugs had been used "off label," tetrabenazine was the first approved treatment for Huntington's disease in the U.S. The compound has been known since the 1950s.
Most common Tetrabenazine side effects from eHealthme
- Fall - (51 reports)
- Depression - (47 reports)
- Dyskinesia - (47 reports)
- Fatigue - (41 reports)
- Akathisia - (35 reports)
- Stress and anxiety - (34 reports)
- Movement - uncontrolled or slow - (33 reports)
- Tardive dyskinesia - (31 reports)
- Hallucinations - (31 reports)
- Eating disorder - (30 reports)
On Feb, 14, 2017 601 people reported to have side effects when taking Tetrabenazine.
Among them, 113 people (18.8%) have Death
On Feb, 01, 2017 601 people reported to have side effects when taking Tetrabenazine. Among them, 31 people (5.16%) have Hallucination
On Feb, 14, 2017 601 people reported to have side effects when taking Tetrabenazine. Among them, 1 person (0.17%) has Hallucination, Auditory